课题基金 / 基金详情

Causes and consequences of interpersonal microbial variation

Causes and consequences of interpersonal microbial variation
人际微生物变异的原因和后果
批准号:
9071690
负责人:
Andrew L Goodman
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-06-10 至 2021-05-31

项目摘要

项目成果

Andrew L Goodman的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Individuals vary widely in drug response. Microbes in the human gastrointestinal tract influence drug metabolism at multiple levels, but we cannot currently predict whether an individual's gut microbial community (microbiota) predisposes them towards efficient or inefficient metabolism of almost any drug. The long-term goals of this research program are to understand the mechanisms that create interpersonal variation in human gut microbial communities and to measure how this variation impacts drug metabolism. We describe experiments that will uncover how three general mechanisms (direct bacterial interaction, small molecule exchange, and host modulation of the microbiota) determine microbiome dynamics. First, wildtype and genetically manipulated human gut symbionts will be studied in vitro and in gnotobiotic mouse models. Next, genomic analyses and epidemiological modeling will be used to connect experimental results from genetically tractable human gut anaerobes to the entire microbiome. Defined assemblies of human gut microbes will then be examined in vitro and in gnotobiotic mice in order to test predictions from the experimental and computational data. In parallel, we will also apply these approaches to dissect the consequences of microbiome variation on metabolism of 5-aminosalicylate (5-ASA), a front-line drug for ulcerative colitis that is directly modified by bacterial enzymes. This proposal presents plan to integrate drug responsiveness results from patients initiating or currently taking 5-ASA with in vitro and gnotobiotic animal studies of 5-ASA metabolism by their microbiomes. Together, these studies will provide key mechanistic insights critical for adding or removing species in human gut microbiomes in a predictable and stable manner; for manipulating individuals' microbiomes in order to improve medical therapy, and for measuring the contribution of the microbiome to individual drug responses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding the contributions of microbiome-encoded drug metabolizing enzymes
  • 批准号:
    10626934
  • 项目类别:
  • 资助金额:
    $41.88万
  • 财政年份:
    2019
  • 负责人:
    Andrew L Goodman
  • 依托单位:
Understanding the contributions of microbiome-encoded drug metabolizing enzymes
  • 批准号:
    10018636
  • 项目类别:
  • 资助金额:
    $41.88万
  • 财政年份:
    2019
  • 负责人:
    Andrew L Goodman
  • 依托单位:
Understanding the contributions of microbiome-encoded drug metabolizing enzymes
  • 批准号:
    10461800
  • 项目类别:
  • 资助金额:
    $41.88万
  • 财政年份:
    2019
  • 负责人:
    Andrew L Goodman
  • 依托单位:
Understanding the contributions of microbiome-encoded drug metabolizing enzymes
  • 批准号:
    9817111
  • 项目类别:
  • 资助金额:
    $41.88万
  • 财政年份:
    2019
  • 负责人:
    Andrew L Goodman
  • 依托单位:
海外基金